Last €25.65 EUR
Change Today +0.60 / 2.37%
Volume 0.0
ILR On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 10:44 AM 12/22/14 All times are local (Market data is delayed by at least 15 minutes).

impax laboratories inc (ILR) Snapshot

Open
€25.12
Previous Close
€25.06
Day High
€25.81
Day Low
€25.09
52 Week High
12/9/14 - €26.48
52 Week Low
02/13/14 - €15.81
Market Cap
1.8B
Average Volume 10 Days
5.1
EPS TTM
--
Shares Outstanding
71.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for IMPAX LABORATORIES INC (ILR)

impax laboratories inc (ILR) Related Businessweek News

No Related Businessweek News Found

impax laboratories inc (ILR) Details

Impax Laboratories, Inc., a specialty pharmaceutical company, develops, manufactures, and markets bioequivalent pharmaceutical products; and develops and markets branded products. The company operates through two segments, Global Pharmaceuticals Division and Impax Pharmaceutical Division. The Global Pharmaceuticals Division develops, manufactures, sells, and distributes generic pharmaceutical products through its global products sales channel for sales of generic prescription products directly to wholesalers, retail drug chains, and others; private label product sales channel for generic over-the-counter (OTC) and prescription products to unrelated third-party customers; Rx partner sales channel for generic prescription products through unrelated third-party pharmaceutical entities; and OTC partner sales channel for OTC products through unrelated third-party pharmaceutical entities, as well as offers research and development services. The Impax Pharmaceutical Division develops proprietary brand pharmaceutical products for the treatment of central nervous system disorders, including migraine, multiple sclerosis, Parkinson’s disease, and postherpetic neuralgia, as well as promotes third-party branded pharmaceutical products through its specialty sales force. The company markets and sells its products to drug wholesalers, warehousing chain drug stores, mass merchandisers, and mail-order pharmacies in the continental United States and the Commonwealth of Puerto Rico. Impax Laboratories, Inc. has a strategic alliance agreement with Teva Pharmaceuticals Curacao N.V to develop and manufacture controlled release generic pharmaceutical products. The company was founded in 1993 and is headquartered in Hayward, California.

973 Employees
Last Reported Date: 02/25/14
Founded in 1993

impax laboratories inc (ILR) Top Compensated Officers

Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $385.0K
President of Impax Pharmaceuticals Division
Total Annual Compensation: $500.5K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $470.2K
Compensation as of Fiscal Year 2013.

impax laboratories inc (ILR) Key Developments

Impax Laboratories, Inc. Announces Consolidated Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Provides Earnings Guidance for the Year 2014

Impax Laboratories Inc. announced consolidated unaudited earnings results for the third quarter and nine months ended September 30, 2014. For the period, the company reported total revenues of $157,999,000 against $132,641,000 a year ago. Income from operations was $25,501,000 against loss from operations of $194,000 a year ago. Income before income taxes was $25,854,000 against $20,000 a year ago. Net income was $15,737,000 against net loss of $180,000 a year ago. Net income per diluted share was $0.22 against $0.00 a year ago. Adjusted net income was $23,396,000 against $16,550,000 a year ago. Adjusted net income per diluted share was $0.33 against $0.25 a year ago. EBITDA was $31,294,000 against $4,993,000 a year ago. Adjusted EBITDA was $48,238,000 against $34,237,000 a year ago. The strong third quarter results were driven by higher sales from key products in the generics business as well as continued growth of Zomig nasal spray in brand division. For the nine months, the company reported total revenues of $464,838,000 against $410,761,000 a year ago. Income from operations was $87,668,000 against $9,847,000 a year ago. Income before income taxes was $88,909,000 against $162,775,000 a year ago. Net income was $57,233,000 against $110,881,000 a year ago. Net income per diluted share was $0.81 against $1.62 a year ago. Net cash provided by operating activities was $53,939,000 against $155,266,000 a year ago. Purchases of property, plant and equipment was $23,968,000 against $24,222,000 a year ago. Adjusted net income was $23,396,000 against $16,550,000 a year ago. Adjusted net income per diluted share was $1.17 against $0.84 a year ago. EBITDA was $104,847,000 against $178,297,000 a year ago. Adjusted EBITDA was $159,239,000 against $113,782,000 a year ago. The company announced that full year 2014 estimates are based on management's current belief about prescription trends, pricing levels, inventory levels, and the anticipated timing of future product launches and event, adjusted gross margins as a % of total revenue are expected to be in the upper 50% range. Capital expenditures are to be approximately $35.0 million (previously $40.0 million to $45.0 million) due to changes in the timing and reprioritization of projects. Effective tax rate is to be approximately 34% (previously 32% to 34%) on a GAAP basis due to product sales mix based on jurisdiction.

Impax Announces R&D Reorganization Designed to Yield Process Improvements and Efficiencies

Impax Laboratories Inc. announced a reorganization of its research and development (R&D) organizations and a prioritization of the project portfolios within the generic and brand businesses. As a result of the reorganization, the generic R&D organization will be responsible for early stage product development and analytical functions for all Impax products, while the brand R&D organization will focus on phase II, III and IV clinical activities, drug safety and pharmacovigilance for all Impax products. This realignment of the R&D organization and reallocation of responsibilities between these teams is intended to better optimize Impax's core technologies and scientific expertise, increase efficiencies and process improvements in key areas and allow Impax to maximize its investment in product development.

Impax Laboratories Inc. Announces the Departure of Carole Ben-Maimon as President of Global Pharmaceuticals

Impax Laboratories Inc. announced that Carole Ben-Maimon, M.D., president of Global Pharmaceuticals, the company's generic pharmaceutical division, has resigned for personal and family reasons. Dr. Ben-Maimon's resignation will be effective November 3, 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ILR:GR €25.65 EUR +0.60

ILR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ILR.
View Industry Companies
 

Industry Analysis

ILR

Industry Average

Valuation ILR Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMPAX LABORATORIES INC, please visit www.impaxlabs.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.